Intron Biotechnology Inc. has entered into an official contract with the U.S. Army Combat Capabilities Development Command (DEVCOM) to develop bacteriophages for combating uropathogenic Escherichia coli (UPEC) infections. DEVCOM, a subcommand of the U.S. Army Futures Command, has been working on a project to develop products that address the risk of urinary tract infections (UTIs) among soldiers exposed to austere environments, such as when deployed or undergoing training.
The Coalition for Epidemic Preparedness Innovations (CEPI) and the International Vaccine Institute (IVI) have announced a renewed collaboration to accelerate the development of vaccines against emerging infectious diseases.
Medicines for Malaria Venture (MMV) has launched a call for new chemical compounds to screen against malaria through its MMV open innovation (MMVoi) initiative. Submissions from both industry and academia allow for compounds that have already been synthesized but not yet tested against malaria to be identified.
Blood cancer drug venetoclax could potentially be used to deplete HIV latently infected cells and delay viral rebound, leading to a potential cure for HIV, according to a study from researchers in Australia who tested the drug in humanized mice models.
The Coalition for Epidemic Preparedness Innovations (CEPI) and the University of Oxford have entered into a strategic partnership to accelerate the development of safe, effective and globally accessible vaccines against ‘disease X,’ the threat of unknown pathogens with the potential to cause pandemics.
Cryptosporidiosis is a parasitic infection caused by Cryptosporidium where infected individuals develop profuse watery diarrhea and enteric symptoms such as abdominal pain. In immunocompromised or malnourished children, the infection may become chronic and lead to significant morbidity and mortality rates.
Viral proteases are well-established therapeutic targets in HIV and hepatitis C virus infections. Following the recent COVID-19 pandemic, one of the strategies in place is SARS-CoV-2 main protease (Mpro) inhibition, given the crucial role of SARS-CoV-2 Mpro in the replication of the virus.
Researchers from Janssen Pharmaceutica NV have reported the discovery of novel hepatitis B virus (HBV) capsid assembly modulators (CAMs) as potential therapeutic candidates against HBV infection. Synthesis and optimization of a new series of di-fluoro azepane HBV CAMs resulted in the identification of compound [I] as the lead candidate with DNA EC50 value of 8.5 nM when assessed in the HepG2.2.15 cellular assay.